Short answer: A useful brief gives the manufacturer a target market, product category, ingredient specification, intended amount, film and pack preferences, evidence needs and expected volume. Mark each item as fixed or negotiable.
Start with the choices that change feasibility
A request for a ‘collagen strip’ leaves too many open questions. Ingredient grade and source, target amount per strip, serving pattern and intended market can change whether the concept fits a practical film. The same is true for caffeine, minerals, oils and botanicals. A good first brief states what the brand has decided and what the developer should test. It also identifies the intended product classification so food, supplement and pharmaceutical assumptions are not mixed.
Use one page for the commercial objective and a second page for technical inputs. Specify the buyer’s target audience and channel, but avoid turning an untested consumer promise into a formula requirement. The product concepts show possible directions; their names do not establish a finished specification.
Brief fields that save a sampling cycle
- Destination market and intended classification
- Ingredient identity, supplier and current specification
- Target per-strip amount and daily-use pattern
- Film size or unit-count constraints
- Flavor direction and exclusions
- Pouch, carton and storage needs
- Required documents, forecast and launch window
Define sample approval before samples arrive
A prototype should answer a question. One round may test loading and handling; another may compare sensory systems. Define the question for each sample set, the measurement method and who will approve it. Record prototype codes, version dates and packaging used for evaluation. If an active changes, a previous taste approval may no longer apply.
The commercial handoff needs its own criteria: agreed specification, analytical method, package construction, artwork, stability plan, batch documents and change-control process. FDA’s dietary supplement CGMP guidance illustrates why specifications and production records are operational requirements in a US supplement project. For a pharmaceutical pathway, ICH Q1A(R2) is a reference for stability study design, but the applicable program must be set for the actual drug product and jurisdiction.
A decision log for the next meeting
- Fixed requirements and negotiable preferences
- Open technical risks and proposed tests
- Owner for regulatory and claim review
- Prototype success criteria
- Documents needed before commercial quotation
Buyer questions
Is a desired launch date enough to obtain a lead time?
No. Timing depends on formulation work, materials, testing, artwork and capacity after scope confirmation.
Should MOQ be fixed in the first brief?
A forecast is useful, but MOQ should follow the chosen formula, pack configuration and production route.
What is the smallest useful first request?
Send the target market, ingredient and amount, intended use, pack concept and the question the first sample should answer.
References and further reading
Last reviewed: . Project parameters remain subject to formula, packaging and target-market review.